Anemia is a condition wherein the blood has low levels of red blood cells (RBC), hemoglobin (oxygen-carrying pigment in whole blood) and/or hematocrit (intact RBC in blood) making it insufficient to address the physiologic needs of the body.
Iron-deficiency anemia is the anemia that resulted from inadequate iron supplementation or excessive blood loss.
It is the most common nutritional disorder worldwide and accounts for more than half of anemia cases.
It is prevalent among preschool children and pregnant women.
New drug applications approved by US FDA as of 16 - 31 January 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.